BLVIS A Blue Vision A

Storaktionærmeddelelse

Storaktionærmeddelelse

Årets meddelelse nr. 18

Dato: 24. marts 2023

Storaktionærmeddelelse

Det skal herved meddeles, at Pharma Equity Group A/S dags dato har modtaget meddelelse om at Jeanette Borgs ejerandel, efter kapitalforhøjelse offentliggjort under selskabsmeddelelse nr. 16 af 24. marts 2023, udgør mindre end 5 %, både direkte og indirekte, af den udstedte aktiekapital i Pharma Equity Group A/S.

Alle henvendelser vedrørende ovenstående bedes venligst rettet til direktør Peter Ole Jensen på e-mail: .



Med venlig hilsen





Pharma Equity Group A/S



På bestyrelsens vegne



EN
24/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Blue Vision A

 PRESS RELEASE

Settlement - Purchase of shares

Settlement - Purchase of shares 2 June 2023 Announcement no. 33 Inside information Settlement - purchase of shares In connection with completion of Pharma Equity Group A/S' (the "Company") purchase of Reponex Pharmaceuticals A/S ("Reponex"), the new shares issued to former larger shareholders in Reponex were subject to a lock-up undertaking (the "Lock-Up Undertaking"). As a shareholder by mistake, and without having obtained consent from the Company, has divested shares in the Company in violation of the Lock-Up Undertaking, such shareholder has, as a consequence, unde...

 PRESS RELEASE

Managers’ transactions

Managers’ transactions May 25,2023  Announcement no. 32     Managers’ transactions   Pharma Equity Group A/S has today received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in Pharma Equity Group A/S made by persons discharging managerial responsibilities in Pharma Equity Group and/or persons closely related with them.           1. Details of the person discharging managerial responsibilities/person closely associated   a) Name      Thomas Kaas Selsø  2. Reason for the notification    a) Position/status    CEO     ...

 PRESS RELEASE

Consolidated interim report 1 January – 31 March 2023

Consolidated interim report 1 January – 31 March 2023 May 10, 2023 Announcement no. 31 Consolidated interim report 1 January – 31 March 2023 Key points (Q1 2023) The transaction with Reponex Pharmaceuticals A/S On 10 May 2023, the Board of Directors and Executive Management of Pharma Equity Group A/S ("PEG" or "the Group") have considered and approved the reviewed consolidated interim report for the period 1 January – 31 March 2023, which has been subject to review performed by the Company’s independent auditor. The comparative figures for 1 January – 31 March 202...

 PRESS RELEASE

Forløb af ordinær generalforsamling i Pharma Equity Group A/S (”Selska...

Forløb af ordinær generalforsamling i Pharma Equity Group A/S (”Selskabet”), den 27. april 2023 Pharma Equity Group A/SÅrets meddelelse nr.: 30Dato: 27. april 2023Forløb af ordinær generalforsamling i Pharma Equity Group A/S (”Selskabet”), den 27. april 2023Den 27. april 2023, kl. 14.00 blev der afholdt ordinær generalforsamling i Selskabet med følgende dagsorden: Bestyrelses beretning om Selskabets virksomhed det forløbne år Fremlæggelse af revideret årsrapport 2022 til godkendelse og meddelelse af decharge for bestyrelsen og direktionen Vedtagelse af fordeling af overskud eller undersku...

 PRESS RELEASE

Biografi på Professor, overlæge dr. med. Peter Vilmann  

Biografi på Professor, overlæge dr. med. Peter Vilmann   Pharma Equity Group A/S Årets meddelelse nr.: 29 Dato: 24. april 2023   Biografi på Professor, overlæge dr. med. Peter Vilmann   Med henvisning til meddelelse nr. 28 af 21. april 2023 har Pharma Equity Group modtaget meddelelse om, at Professor Peter Vilmann opstiller som kandidat til bestyrelsen på selskabets ordinære generalforsamling den 27. april 2023.   Professor, overlæge dr. med. Peter Vilmann er født i 1952, er cand.med. fra Københavns Universitet i 1981, speciallæge i kirurgi og kirurgiske mavetarmsygdomme, er klinisk ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch